Eli Lilly price target raised to $1,182 from $1,038 at Truist

Truist analyst Srikripa Devarakonda raised the firm’s price target on Eli Lilly (LLY) to $1,182 from $1,038 and keeps a Buy rating on the shares. The firm is positive on the stock based on the recently announced White House deal that provides reimbursement for weight loss medications to Medicare patients, the analyst tells investors in a research note. Truist adds that it expects orforglipron to be on the market in the first half of 2026 and believes that the competitive profiles of Zebpound and orforglipron will continue to support Eli Lilly leadership in the obesity landscape.